Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications.
about
In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection modelImportance of relating efficacy measures to unbound drug concentrations for anti-infective agentsA mini review on pyridoacridines: Prospective lead compounds in medicinal chemistryStructural studies of bovine, equine, and leporine serum albumin complexes with naproxenDefining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic ApproachExpedient Synthesis of SMAMPs via Click Chemistry.Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.Probenecid: an unexplained effect on cephalosporin pharmacology.Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers.Pharmacokinetics of single- and multiple-dose teicoplanin in healthy volunteers.Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil.Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteersMultiple-dose pharmacokinetics of intravenously administered cefoperazone and sulbactam when given in combination to infected, seriously ill, elderly patients.Pharmacokinetics of aztreonam in patients with gram-negative infections.Canine model for the simultaneous measurement of antibiotic levels in tissues and bacterial killing rate.Antifungal pharmacokinetics and pharmacodynamicsIssues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.Determination of Cefalothin and Cefazolin in Human Plasma, Urine and Peritoneal Dialysate by UHPLC-MS/MS: application to a pilot pharmacokinetic study in humans.Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response.Protein binding of antimicrobials: methods for quantification and for investigation of its impact on bacterial killing.The use of antibiotic serum levels to predict concentrations in tissues.Charge and lipophilicity govern the pharmacokinetics of glycopeptide antibiotics.A model of cefoperazone tissue penetration: diffusion coefficient and protein binding.Mezlocillin pharmacokinetics after single intravenous doses to patients with varying degrees of renal function.Distribution of oxytetracycline to tissue cages and granuloma pouches in calves and effect of acute inflammation on distribution to tissue cages.Pharmacokinetics and efficacy of structurally related spirohydantoin and spirosuccinimide aldose reductase inhibitors.
P2860
Q24654780-5AF92DAB-A6BC-41BD-91D8-129842E25FC4Q26827380-CDDBAF70-1CA4-467E-A393-8AD52EC66FA4Q26828896-BE6DA632-DD3C-4592-8ACE-213BBC189DBDQ27690084-8EC0214D-F66E-4542-AA09-FABC104A7761Q28601378-6907C933-D82D-4CDF-8F28-FAE411AC30F8Q33749813-780218A6-66EF-4F42-8569-8C9A92DA307FQ34510488-03EC4FF6-5392-4BF1-9E60-98B2252A7024Q34518155-CAF2F5D1-8763-4E76-93D5-568C6F855027Q35121357-7FADDDE8-4EF3-49BB-852D-77774D24337FQ35243618-25EEF66D-4776-45A6-BA61-F72B2C16B3F2Q35260298-1CCA3882-D042-4623-B20D-4440E524F464Q35294133-A41A9465-38F2-43C2-933B-CEC1A70CFFC2Q35305116-F9B4856F-0591-4C8D-B954-F3FEBB1D2E6CQ35568767-C2BDFC5F-04BA-4322-9F31-3FE2EB57280BQ35650217-A38B3AFF-9971-458B-B7A5-4939799B9A9CQ35663841-F821182D-D982-4762-9919-538A659761BAQ35754443-4C0A9FE7-FAE4-461D-BD6E-CE225370D7FCQ35783893-480F3AD7-3062-4BC3-8311-5A02798B709CQ36083619-4D5A6084-0D96-48D3-8A8D-563DB4044635Q36863646-8E249165-B10A-4EB2-ABD4-622B4251138BQ37149078-BB8222A7-1296-4C36-8F6C-7D77937AD6ABQ39746890-CDE503CE-8F43-4D3B-8824-075EA00A7066Q39850906-14FBAAB5-D161-444F-A112-F04B05A3F73CQ39867633-36F98C31-4852-42B3-A616-1C192E8A3B0FQ40281838-58A9C15B-14B1-49B0-8BAE-922236BE89C7Q50183232-AC002552-01D1-4BFC-B069-F6B7754D773BQ51692241-04E40588-BF1F-422B-9FD5-AADCC0B40460
P2860
Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 1977
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications.
@en
Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications.
@nl
type
label
Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications.
@en
Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications.
@nl
prefLabel
Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications.
@en
Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications.
@nl
P1476
Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications.
@en
P2093
P304
P356
10.2165/00003088-197702040-00002
P577
1977-07-01T00:00:00Z
P6179
1014654556